Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), confirmed by a specialist pathologist.
• People with newly diagnosed NLPHL at stage IB through stage IV, or people who have already received treatment for NLPHL at any stage.
• People whose treating doctor has decided that observation alone is not appropriate and that treatment is needed — for example, because of unexplained fever, unexplained significant weight loss, drenching night sweats, uncomfortable swollen lymph nodes or disease in other organs, or personal preference.
• People whose disease can be measured on scans according to standard lymphoma criteria.
• People aged 18 years or older.
• People with a reasonable level of general physical functioning (able to care for themselves and carry out some daily activities).
• People with blood counts, liver function, and kidney function within acceptable ranges as determined by blood tests.
• People living with HIV who are on effective treatment and have had an undetectable level of virus in the blood within the past 6 months.
• People with a history of hepatitis B who have an undetectable viral level while on appropriate suppressive treatment.
• People with a history of hepatitis C who have been successfully treated and cured, or who are currently on treatment with an undetectable viral level.
• People who have or have had another cancer, provided that cancer and its treatment are unlikely to interfere with this trial's safety or results, as determined by the trial site.
• People with a known heart condition or history of heart-related treatment, provided a heart function assessment places them in a satisfactory category (New York Heart Association class 2B or better).
• People who are able to use reliable contraception throughout the trial and for a specified period afterward (at least 3 months after the last dose of one study drug and 12 months after the last dose of the other), and who are willing to inform their doctor immediately if pregnancy occurs or is suspected during participation.
• People who are able to understand the study and are willing to sign a consent form (or have a legal representative do so on their behalf).

Who may not be able to join:

• People diagnosed with classical Hodgkin lymphoma or a combined (composite) lymphoma rather than NLPHL.
• People whose NLPHL has transformed into a more aggressive lymphoma, or where the treating doctor suspects this may have occurred or believes stronger chemotherapy is needed.
• People whose NLPHL has come back within 6 months of completing a treatment that included rituximab.
• People who are still experiencing significant side effects (above a mild level, with the exception of hair loss) from a previous cancer treatment.
• People currently taking part in another clinical trial involving an experimental treatment.
• People whose lymphoma has spread to the brain or spinal cord.
• People with a known history of serious allergic reactions to drugs that are chemically or biologically similar to the study drugs (mosunetuzumab or rituximab).
• People with uncontrolled ongoing illness or any other serious condition that the trial site determines would make participation unsafe.
• People who are pregnant, as the effect of the study drugs on an unborn baby is unknown.
• People who are breastfeeding, as the study drugs may pass to the infant through breast milk.
• People who have previously received a donor stem cell transplant or a solid organ transplant (such as a kidney or liver transplant).
• People who have received a live or live-attenuated vaccine (such as the nasal flu vaccine) within 4 weeks before starting the trial, or who may need one during the trial.
• People who have received any other cancer treatment — whether experimental or standard — within approximately 4 weeks before starting the trial (or within 5 half-lives of that drug, whichever is shorter).
• People with significant heart disease, such as a heart attack in the past 6 months, unstable heart rhythm, or unstable chest pain (confirm with trial site).
• People with significant lung disease, such as severe obstructive pulmonary disease or a history of bronchospasm.
• People with a current or past history of certain brain or nervous system conditions, such as stroke with ongoing effects, epilepsy with a recent seizure, brain blood vessel inflammation, or a degenerative neurological disease — though some exceptions may apply (confirm with trial site).
• People with a confirmed history of a rare and serious brain infection called progressive multifocal leukoencephalopathy (PML).
• People with an active serious infection requiring hospital treatment or intravenous antibiotics within the past 4 weeks, or a known active infection of any kind at the time of enrolment.
• People who have taken immune-suppressing medications (such as methotrexate, azathioprine, or similar drugs) within 2 weeks before starting the trial.
• People with a known or suspected chronic active infection with Epstein-Barr virus (EBV) or cytomegalovirus (CMV).
• People with a known or suspected history of a serious immune condition called hemophagocytic lymphohistiocytosis (HLH).

Important: Always verify eligibility with the trial site directly before applying.